Travere Therapeutics upgraded by Piper Sandler with a new price target
$TVTX
Biotechnology: Pharmaceutical Preparations
Health Care
Piper Sandler upgraded Travere Therapeutics from Neutral to Overweight and set a new price target of $49.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/14/2026 | $49.00 | Neutral → Overweight | Piper Sandler |
| 10/31/2025 | $34.00 → $48.00 | Buy | Citigroup |
| 6/11/2025 | $30.00 | Buy | H.C. Wainwright |
| 6/11/2025 | $35.00 → $32.00 | Buy | Citigroup |
| 1/10/2025 | Overweight | Cantor Fitzgerald | |
| 10/21/2024 | $9.00 → $27.00 | Equal Weight → Overweight | Wells Fargo |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 9/9/2024 | $25.00 | Neutral → Buy | Guggenheim |
FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI JUPITER, Fla., April 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Travere Therapeutics, Inc. (NASDAQ:TVTX) has received approval from the U.S. Food and Drug Administration (FDA) for FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. FILSPARI is the first and only medicine approved by the FDA for the treatment of FSGS,
FILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndrome Additional indication for FILSPARI expands total addressable population to more than 100,000 patients in the U.S, including more than 30,000 patients with FSGS Label aligns with KDIGO clinical practice guidelines for managing patients with FSGS Company to host conference call April 13, 2026, at 6:45 p.m. ET Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulo
U.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908 new PSFs received during the quarter U.S. net product sales of FILSPARI totaled $322 million for full year 2025; total net product sales were $410 million for full year 2025 PDUFA target action date for FILSPARI in FSGS is April 13, 2026; Company positioned for a successful commercial launch, if approved Enrollment activities have resumed for the pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update.
Piper Sandler upgraded Travere Therapeutics from Neutral to Overweight and set a new price target of $49.00
Citigroup reiterated coverage of Travere Therapeutics with a rating of Buy and set a new price target of $48.00 from $34.00 previously
H.C. Wainwright resumed coverage of Travere Therapeutics with a rating of Buy and set a new price target of $30.00
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
4 - Travere Therapeutics, Inc. (0001438533) (Issuer)
8-K - Travere Therapeutics, Inc. (0001438533) (Filer)
DEFA14A - Travere Therapeutics, Inc. (0001438533) (Filer)
DEF 14A - Travere Therapeutics, Inc. (0001438533) (Filer)
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
SC 13G - Travere Therapeutics, Inc. (0001438533) (Subject)
SC 13G/A - Travere Therapeutics, Inc. (0001438533) (Subject)
FILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndrome Additional indication for FILSPARI expands total addressable population to more than 100,000 patients in the U.S, including more than 30,000 patients with FSGS Label aligns with KDIGO clinical practice guidelines for managing patients with FSGS Company to host conference call April 13, 2026, at 6:45 p.m. ET Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulo
U.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908 new PSFs received during the quarter U.S. net product sales of FILSPARI totaled $322 million for full year 2025; total net product sales were $410 million for full year 2025 PDUFA target action date for FILSPARI in FSGS is April 13, 2026; Company positioned for a successful commercial launch, if approved Enrollment activities have resumed for the pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update.
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a bi
Meissa Vaccines ("Meissa"), a clinical-stage biotechnology company developing vaccines to prevent viral respiratory infections, today announced the appointment of Frank Glavin as Chief Executive Officer, bringing more than 20 years of biotech and pharma experience across the biotech value chain from early-stage research through to commercial planning and business development. Martin Moore, Ph.D., cofounder of Meissa, will serve as the Company's Chief Scientific Officer. "I am excited to welcome Frank to the Meissa leadership team," said Dr. Moore. "We are at an important stage in Meissa's growth, and Frank brings extensive, complementary experience in commercial planning, business developm
Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig brings to Travere more than 15 years of expertise in medical oversight, drug development, clinical trial planning and execution and global regulatory engagement. Dr. Inrig joins the Company as it prepares for accelerated approval submissions of sparsentan for IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) in 2022, as well as the continued advancement of its pegtibatinase program in classical homocystinuria (HCU). "We are excited to welcome Jula to the Travere Therapeutics